FDA Approves Interchangeable Biosimilars For Ophthalmology Drug Eylea

By Gabrielle Wanneh / May 20, 2024 at 5:25 PM
The competition is on for Regeneron’s costly eye disorder treatment Eylea as FDA on Monday (May 20) approved Biocon Biologics’ Yesafili (aflibercept-jbvf) and Samsung Bioepis’ Opuviz (aflibercecpt-yszy), the first two interchangeable biosimilars available for the brand drug, meaning either biosimilar can be substituted for Eylea without the need to consult a prescriber. Kaiser Family Foundation reported in March 2022 that the average Medicare beneficiary liability for Eylea, the top-spending Part B drug in 2019 and used by 270,300 traditional Medicare...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.